# First three medicines after ibuprofen: selection and review record

## Selection rule

“Most popular” is ambiguous. For this prototype, the next three entries use total U.S. outpatient prescription fills in ClinCalc's 2024 Top 300, based on AHRQ MEPS data. It is not a global-use or public-interest ranking, and fills are not unique people.

| U.S. 2024 fill rank | Medicine | Estimated fills |
|---:|---|---:|
| 1 | Atorvastatin | 115,678,209 |
| 2 | Levothyroxine | 82,380,627 |
| 3 | Metformin | 82,288,616 |

Sources: [ClinCalc Top 300 of 2024](https://clincalc.com/DrugStats/Top300Drugs.aspx); [AHRQ MEPS prescription medicines data](https://meps.ahrq.gov/data_stats/download_data/pufs/h254a/h254adoc.shtml).

## Claim checks and boundaries

- **Atorvastatin:** the FDA/DailyMed label describes competitive HMG-CoA reductase inhibition. It notes hepatic cholesterol-synthesis effects and increased hepatic LDL receptors in animal models; do not present the animal-model pathway demonstration as direct clinical imaging. The liver is the main site of action. The story describes the pathway and lipid outcome without inferring any individual's response. [DailyMed Lipitor label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a60cc18b-0631-4cf0-b021-9f52224ece65), [MedlinePlus](https://medlineplus.gov/druginfo/meds/a600045.html).
- **Levothyroxine:** the label identifies it as synthetic T4 and explains T4/T3 binding to thyroid receptors associated with DNA. Food, supplements and other medicines can change absorption; the story does not give timing or dose instructions. [DailyMed levothyroxine label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=609352a9-740f-4874-997b-60b58d0c2b8a), [MedlinePlus](https://medlineplus.gov/druginfo/meds/a682461.html).
- **Metformin:** label §12.1 lists decreased hepatic glucose production, decreased intestinal glucose absorption and improved insulin sensitivity by increasing peripheral glucose uptake and use. It does not name one molecular target explaining all three listed effects. The story shows those organ-level effects separately and leaves a proposed single target open; it does not describe mitochondrial proposals as settled fact. [DailyMed metformin label](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=2be73d5e-7682-4ad3-831b-8c1ea73e38de&type=pdf), [MedlinePlus](https://medlineplus.gov/druginfo/meds/a696005.html).
- **Metoprolol succinate ER:** DailyMed describes preferential beta-1 adrenergic receptor blockade, reduced sinus rate and AV-nodal conduction, and attenuation of catecholamine-related increases in heart rate and myocardial contractility. It says selectivity is not absolute at higher plasma concentrations, when beta-2 receptors may also be inhibited. A linked PNAS primary study supplies adult ventricular cardiomyocyte beta-1 receptor localization context; it does not measure metoprolol binding, occupancy or an individual response. The cell scene is schematic and qualitative. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7dfe56fe-68b6-4897-9238-0f530c92e27e), [PNAS study](https://pubmed.ncbi.nlm.nih.gov/34088840/).

These are concise educational drafts. A qualified clinician or pharmacist must check clinical accuracy and safety, and a native language reviewer must check every non-English translation before the content is used as patient-facing medical education. The web speech voice is selected from those installed on the visitor's device, so sound and pronunciation vary by device. New medicine pages use an animated chapter highlight with a simplified step sequence; the animations are teaching aids, not measured molecular or whole-body simulations.